tiprankstipranks
Advertisement
Advertisement

KPRX Stock Latest News

KPRX Earnings this Week: How Will it Perform?
Pre-EarningsKPRX Earnings this Week: How Will it Perform?
1d ago
KPRX
Strategic Financing and Differentiated KIO‑301 Pipeline Underpin Buy Rating on Kiora Pharmaceuticals (KPRX)
PremiumRatings
Strategic Financing and Differentiated KIO‑301 Pipeline Underpin Buy Rating on Kiora Pharmaceuticals (KPRX)
29d ago
KPRX
Kiora Pharmaceuticals Announces $5 Million Private Placement Financing
PremiumCompany Announcements
Kiora Pharmaceuticals Announces $5 Million Private Placement Financing
1M ago
8K
KPRX
Kiora Pharmaceuticals Announces Chief Development Officer Resignation
PremiumCompany Announcements
Kiora Pharmaceuticals Announces Chief Development Officer Resignation
1M ago
8K
KPRX
Clinical and Market Validation of Kiora’s Lead Programs Underpin Buy Rating and $12 Price Target
PremiumRatings
Clinical and Market Validation of Kiora’s Lead Programs Underpin Buy Rating and $12 Price Target
2M ago
KPRX
Kiora Pharmaceuticals: Strong Financial Position and Promising Clinical Developments Drive Buy Rating
PremiumRatingsKiora Pharmaceuticals: Strong Financial Position and Promising Clinical Developments Drive Buy Rating
6M ago
KPRX
Kiora Pharmaceuticals Reports Improved Financial Performance
Premium
Company Announcements
Kiora Pharmaceuticals Reports Improved Financial Performance
6M ago
KPRX
Kiora Pharmaceuticals Advances Phase II Study for Retinitis Pigmentosa Treatment
Premium
Company Announcements
Kiora Pharmaceuticals Advances Phase II Study for Retinitis Pigmentosa Treatment
6M ago
KPRX
Kiora Pharmaceuticals Advances Promising Eye Treatment with KIO-301 Study
PremiumCompany Announcements
Kiora Pharmaceuticals Advances Promising Eye Treatment with KIO-301 Study
6M ago
KPRX
Kiora Pharmaceuticals’ KIO-104: A Promising Treatment for Macular Edema?
PremiumCompany Announcements
Kiora Pharmaceuticals’ KIO-104: A Promising Treatment for Macular Edema?
6M ago
KPRX
Kiora Pharmaceuticals files $100M mixed securities shelf
PremiumThe Fly
Kiora Pharmaceuticals files $100M mixed securities shelf
8M ago
KPRX
Kiora Pharmaceuticals Highlights at Ophthalmology Conference
PremiumCompany Announcements
Kiora Pharmaceuticals Highlights at Ophthalmology Conference
9M ago
8K
KPRX
Promising Developments and Strategic Partnerships Drive Buy Rating for Kiora Pharmaceuticals
PremiumRatingsPromising Developments and Strategic Partnerships Drive Buy Rating for Kiora Pharmaceuticals
9M ago
KPRX
Kiora Pharmaceuticals Advances Retinal Disease Pipeline
Premium
Company Announcements
Kiora Pharmaceuticals Advances Retinal Disease Pipeline
9M ago
KPRX
Positive Outlook for Kiora Pharmaceuticals: Buy Rating Affirmed Amid Promising Developments and Strategic Initiatives
Premium
Ratings
Positive Outlook for Kiora Pharmaceuticals: Buy Rating Affirmed Amid Promising Developments and Strategic Initiatives
10M ago
KPRX
Kiora Pharmaceuticals granted new patent for KIO-104, says H.C. Wainwright
PremiumThe Fly
Kiora Pharmaceuticals granted new patent for KIO-104, says H.C. Wainwright
10M ago
KPRX
Kiora Pharmaceuticals Holds Annual Meeting, Elects Directors
PremiumCompany Announcements
Kiora Pharmaceuticals Holds Annual Meeting, Elects Directors
11M ago
8K
KPRX
Kiora Pharmaceuticals: Strategic Partnerships and Promising Financial Prospects Drive Buy Rating
PremiumRatings
Kiora Pharmaceuticals: Strategic Partnerships and Promising Financial Prospects Drive Buy Rating
11M ago
KPRX
Kiora Pharmaceuticals Secures Exclusive Option Agreement with Senju
PremiumCompany Announcements
Kiora Pharmaceuticals Secures Exclusive Option Agreement with Senju
11M ago
8K
KPRX
Kiora Pharmaceuticals Reports Q1 2025 Financial Results
PremiumCompany AnnouncementsKiora Pharmaceuticals Reports Q1 2025 Financial Results
11M ago
KPRX
Kiora Pharmaceuticals: Strong Financial Position and Strategic Partnerships Propel Buy Rating
Premium
Ratings
Kiora Pharmaceuticals: Strong Financial Position and Strategic Partnerships Propel Buy Rating
12M ago
KPRX
Kiora Pharmaceuticals’ KIO-104: Promising Preclinical Data and Strong Buy Rating
Premium
Ratings
Kiora Pharmaceuticals’ KIO-104: Promising Preclinical Data and Strong Buy Rating
1y ago
KPRX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >